Reports Q4 revenue $343.3M, consensus $329.11M. Chris Simon, Haemonetics’ CEO, stated: “Fourth quarter and fiscal 2024 performance was strong. We advanced our market leadership and portfolio evolution by investing selectively, acquiring attractive new products and rationalizing non-strategic assets to accelerate revenue growth and margin expansion. Midway through our long-range plan we are on track to deliver increased value to our customers and our shareholders.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics (HAE) Q4 Earnings Cheat Sheet
- Haemonetics Corp. Secures New Credit for Strategic Growth
- Haemonetics receives FDA clearance for TEG 6s Global Hemostasis-HN cartridge
- Haemonetic sees Attune Medical acquisition adding $30M-$35M in revenue in FY25
- Haemonetics Corporation Completes Acquisition of Attune Medical